AstraZeneca Results Presentation Deck
Reported profit and loss
Total Revenue
- Product Sales
- Collaboration Revenue
Gross margin
Operating expenses¹
- R&D expenses
- SG&A expenses
Other operating income
Operating profit
Tax rate
EPS
FY 2021
$m
37,417
36,541
876
66.0%
25,416
9,736
15,234
1,492
1,056
143.4%
$0.08
CER change
%
38
38
20
(12.6) pp
40
59
32
(4)
(70)
(84)
% total
revenue
100
98
2
68
26
41
4
3
Q4 2021
$m
12,011
11,498
513
59.8%
7,825
2,584
5,117
147
(292)
45.6%
($0.22)
12 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales.
1. Includes distribution expenses. R&D = research and development; SG&A = sales, general and administration; pp = percentage points; n/m = growth rate not meaningful.
CER change
%
63
65
29
(16.0) pp
55
50
59
(78)
(105)
(113)
% total
revenue
100
96
4
65
22
43
1
(2)
4View entire presentation